保肾口服液治疗IgA肾病小鼠的实验研究

目的:探讨保肾口服液对实验性IgA肾病小鼠的作用机理.方法:采用口服牛血清白蛋白及静注葡萄糖球菌肠毒素制成的小鼠IgA肾病模型,分析保肾口服液的作用机理.结果:保肾口服液大剂量组对降低小鼠尿红细胞计数最为明显;小鼠血清IgA含量组间比较未见显著性统计学差异;3个剂量的保肾口服液治疗组比潘生丁治疗组肾组织IgA荧光强度弱,潘生丁治疗组比肾炎康复片组肾组织IgA荧光强度弱.3个剂量的保肾口服液组IgA荧光强度比较未见明显变化;5个治疗组肾小球轻度增大,系膜细胞和系膜基质增生的程度较病理组均轻,系膜细胞数较病理组少,毛细血管管腔受压不明显.结论:保肾口服液能降低IgA肾病小鼠尿红细胞,减少肾组织中IgA的沉积,抑制系膜细胞和系膜基质的增生.

Experimental Study on Therapeutic Effect of Kidney Protection Liquid on IgA Nephropathy rat model

Objection:To evaluate the mechanism of KPL on experimental IgA Nephropathy rat model.Methods:To study the mechanism of KPL,the IgA Nephropathy rat model was copied by the methods of oral taking BSA and vein injection of SEB.Results:The large dosage KPL group had significant function of reducing the urine RBC and IgA immunofluorescence;density of the KPL groups was lower than Persantine group.There is no obvious difference among the 3 KPL groups in IgA immunofluorescence.The Kidney biopsy damage of glomerulus,measagnial cell,mesangial matrix cell among 5 Treatment group was mild.Conclusion:The KPL can reduce the microscopic heamaturia and deposits of the protein immunoglobulin A inside the glomeruli within the kindney.